104 related articles for article (PubMed ID: 38730415)
1. Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma.
Yue P; Bie F; Zhu J; Gao LR; Zhou Z; Bai G; Wang X; Zhao Z; Xiao ZF; Li Y; Zhou A; Liu WY; Jiao Y; Gao S
Mol Cancer; 2024 May; 23(1):96. PubMed ID: 38730415
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
[TBL] [Abstract][Full Text] [Related]
3. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
5. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
[No Abstract] [Full Text] [Related]
6. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
[TBL] [Abstract][Full Text] [Related]
7. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.
Nobel TB; Barbetta A; Hsu M; Tan KS; Pinchinat T; Schlottmann F; Bains MS; Ku GY; Wu AJ; Patti MG; Jones DR; Molena D
J Gastrointest Surg; 2019 Jan; 23(1):11-22. PubMed ID: 30215197
[TBL] [Abstract][Full Text] [Related]
11. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
13. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
14. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
[TBL] [Abstract][Full Text] [Related]
15. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
17. Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation.
Hsu FM; Cheng JC; Chang YL; Lee JM; Koong AC; Chuang EY
Sci Rep; 2015 May; 5():10291. PubMed ID: 25980316
[TBL] [Abstract][Full Text] [Related]
18. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
[TBL] [Abstract][Full Text] [Related]
19. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
[TBL] [Abstract][Full Text] [Related]
20. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]